Medtronic PLC reported its Q3 FY2025 earnings, revealing an adjusted earnings per share (EPS) of $1.39, surpassing estimates of $1.36 and reflecting a year-over-year increase of 7%. The company's revenue was reported at $8.29 billion, slightly missing the expected $8.33 billion, but still showing a 2.5% increase compared to the previous year. The adjusted net income for the quarter was $1.79 billion, exceeding estimates of $1.74 billion and marking a 3% year-over-year growth. Medtronic also provided guidance for the full fiscal year 2025, projecting an adjusted EPS between $5.44 and $5.50. The company highlighted strong performance in key segments such as Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation.